Oxford Cannabinoid Technologies

OCT was established in 2017 by UK private equity firm Kingsley Capital Partners, as a biopharmaceutical company focused on cannabinoid drug development. The company’s vision is to become the global leader in developing prescription medicines that target the endocannabinoid system and address significant unmet medical needs.

To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids, and other drug candidates.

Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed two rounds of investment.